← Back to Search

Radiopharmaceutical

SPECT/CT Dosimetry for Prostate Cancer (SPECTacular Trial)

N/A

Recruiting

Research Sponsored by BAMF Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediately after the completion of spect/ct scanning.

Awards & highlights

SPECTacular Trial Summary

This trial will test if radiation doses can be estimated more accurately during PSMA-targeted radioligand therapy. Patients will receive 5 extra scans.

Who is the study for?

Men over 18 with confirmed prostate adenocarcinoma, who can lay flat for up to 2 hours and are undergoing PSMA-targeted Radioligand Therapy. They must consent to study procedures and be available throughout the study. Those with performance status ≥2 or conditions preventing standard Lu-177 PSMA therapy cannot participate.Check my eligibility

What is being tested?

The SPECTacular Study is testing additional SPECT/CT scans in patients already receiving PSMA-targeted Radioligand treatments for prostate cancer. It aims to compare different methods of measuring absorbed radiation doses during treatment cycles.See study design

What are the potential side effects?

While the trial focuses on imaging techniques rather than new medications, potential side effects may stem from prolonged exposure to radioligands used in therapy, such as fatigue, nausea, dry mouth or changes in blood counts.

SPECTacular Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediately after the completion of spect/ct scanning.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediately after the completion of spect/ct scanning.

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after the completion of spect/ct scanning. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dosimetry Method

SPECTacular Trial Design

1Treatment groups

Experimental Treatment

Group I: SPECT/CTExperimental Treatment1 Intervention

All patients enrolled will undergo 5 additional (6 total) SPECT/CT scans per treatment cycle. Current FDA approved PSMA radioligand therapy is administered over 6 cycles, so there will be a total of 30 additional SPECT/CT scans during this study. During each treatment cycle, patients will have a SPECT/CT scan at the following time points after administration of PRLT: 4 Hours 24 Hours (+/- 8 Hours) 48 Hours (+/- 8 Hours) 96 Hours (+/- 8 Hours) 168 Hours (+/- 24 Hours) 336 Hours (+/- 24 Hours)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SPECT/CT

2014

N/A

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

BAMF HealthLead Sponsor

1 Previous Clinical Trials

100 Total Patients Enrolled

Media Library

PSMA-targeted Radioligand Therapy (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT05823402 — N/A

Prostate Cancer Research Study Groups: SPECT/CT

Prostate Cancer Clinical Trial 2023: PSMA-targeted Radioligand Therapy Highlights & Side Effects. Trial Name: NCT05823402 — N/A

PSMA-targeted Radioligand Therapy (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05823402 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available berths in this clinical trial?

"As verified on clinicaltrials.gov, recruitment for the trial is still ongoing. This medical project was initially announced April 17th 2023 and amended two days later."

Answered by AI

How many participants are registered for this experiment?

"Correct. According to clinicaltrials.gov, this study posted on April 17th of 2023 is currently recruiting participants. 30 volunteers are expected from 1 site in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

2023. "Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05823402.